Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
about
BRAF inhibitors: resistance and the promise of combination treatments for melanoma.The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma.Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
P2860
Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ongoing Response in BRAF V600E ...... afenib Therapy: A Case Report.
@en
Ongoing Response in BRAF V600E ...... afenib Therapy: A Case Report.
@nl
type
label
Ongoing Response in BRAF V600E ...... afenib Therapy: A Case Report.
@en
Ongoing Response in BRAF V600E ...... afenib Therapy: A Case Report.
@nl
prefLabel
Ongoing Response in BRAF V600E ...... afenib Therapy: A Case Report.
@en
Ongoing Response in BRAF V600E ...... afenib Therapy: A Case Report.
@nl
P2093
P2860
P1433
P1476
Ongoing Response in BRAF V600E ...... afenib Therapy: A Case Report.
@en
P2093
Andrew J Dooley
Avinash Gupta
Mark R Middleton
P2860
P2888
P304
P356
10.1007/S11523-015-0410-9
P577
2016-02-09T00:00:00Z